ZBTB16::RARA Variant Acute Promyelocytic Leukemia (vAPL) Treated with Gemtuzumab Ozogamicin (GO) with Unique Pathology and Genetic Findings

Authors

Jason A. Adler, Case Western Reserve University
Ramya Gadde, Case Western Reserve University
Benjamin K. Tomlinson, Case Western Reserve UniversityFollow
Shahirekha Shetty, Case Western Reserve UniversityFollow

Document Type

Article

Publication Date

7-26-2023

Manuscript Version

vor

Publication Title

British Journal of Haematology

Rights

© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Recommended Citation

Kassem, A.M., Keinath, M.C., Adler, J., Gadde, R., Tomlinson, B. and Shetty, S. (2023), ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings. Br J Haematol, 202: 1077-1078. https://doi.org/10.1111/bjh.18950